Join or renew today
Regulators, politicians, employers and insurers have assured Americans that generic drugs – which will soon comprise 80 percent of the medicine dispensed to us – are safe, effective, and largely identical to their more expensive brand-name counterparts. "Bad Bargain" exposes the glaring regulatory loopholes that allow substandard or un-equivalent generics to reach consumers. The article also identified patients who suffered devastating consequences after being switched from brand-name to generic drugs.
The page you have requested is available to AHCJ members only. If you are
a member, please login below.
If you're not a member, we invite you to join us. Read about member
benefits and how to join.
Please provide your user ID and password below:
~ or ~
Log in by email, using your email address: